In The News

FDA Approves Short-Acting Insulin Admelog to Treat Diabetes

December 11, 2017. The US Food and Drug Administration (FDA) announced the approval of Admelog (insulin lispro injection), a short-acting insulin indicated to improve blood glucose control in adult and pediatric patients ≥3 years of age with type 1 diabetes and adults with type 2 diabetes. Admelog is the first short-acting insulin approved as a “follow-on” product via the FDA’s 505(b)(2) pathway. It is recommended that healthcare providers monitor potassium levels in patients taking Admelog who are at risk for hypokalemia.

FDA Approves Once-Weekly Semaglutide for T2DM

December 5, 2017. The US Food and Drug Administration (FDA) has approved the once-weekly injectable glucagon-like peptide-1 receptor agonist semaglutide (0.5 and 1.0 mg doses) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. This approval was predicated on data from 8 major clinical trials, comprising more than 8,000 patients, and including a FDA-mandated cardiovascular outcomes trial.

DEVOTE: Temporal Relationships Between Severe Hypoglycemia, Cardiovascular Outcomes, and Mortality

September 15, 2017. This secondary analysis of the double-blind Trial Comparing Cardiovascular Safety of Insulin Degludec vs Insulin Glargine in Patients with Type 2 Diabetes at High Risk of Cardiovascular Events(DEVOTE) evaluated the association between severe hypoglycemia (SH) and cardiovascular (CV) outcomes/mortality in patients randomly assigned to once-daily treatment with either insulin degludec or insulin glargine U100.

Risk Factors for Severe Hypoglycemia in Adults With Diabetes

December 1, 2017. Assessing hypoglycemia risk is essential when individualizing diabetes care. This studied aimed to evaluate risk factors for severe hypoglycemia over a median 15.2 years among 1,206 participants with diabetes, using data from the ongoing, prospective Atherosclerosis Risk in Communities (ARIC) cohort study. Mean participant age was 64 years, 46% were male, and 32% were black.

AACE and Endocrine Society Work Together to Improve Insulin Affordability and Access

November 20, 2017. The American Association of Clinical Endocrinologists and the Endocrine Society have introduced a resolution at the 2017 Interim Meeting of the American Medical Association House of Delegates to improve insulin affordability for the millions of Americans with diabetes who inject insulin daily. The resolution seeks a summit to identify solutions to dramatic insulin cost increases, reduce patient cost-sharing, curb nonmedical insulin switching, facilitate greater insulin pricing transparency, and integrate drug formularies into electronic medical records.

Canagliflozin Reduces Cardiovascular Events in Patients With Type 2 Diabetes Regardless of Cardiovascular Disease History

November 13, 2017. A prespecified data analysis from the Canagliflozin Cardiovascular Assessment Study (CANVAS) found that canagliflozin, a sodium glucose cotransporter 2 (SGLT-2) inhibitor, reduced cardiovascular (CV) events in patients with type 2 diabetes and with and without a history of CV disease (the secondary prevention cohort, n=6,656, and primary prevention cohort, n=3,486, respectively). The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.

National Clinical Care Commission Act Becomes Public Law

November 2, 2017. President Trump has signed the National Clinical Care Commission Act (S. 920) to establish a public/private commission of experts and patient advocacy representatives to collectively assess federal government diabetes programs, identify inefficiencies and gaps, and provide recommendations to the US Department of Health and Human Services and Congress to improve diabetes care. Congratulations to all AACE advocates, the broad diabetes community, and industry partners who worked to support this legislation.

Insulin Degludec Is Effective in Patients With Type 1 or Type 2 Diabetes After Switching Basal Insulin

November 6, 2017. This European, multicenter, retrospective chart review (EU-TREAT) found that switching patients with type 1 or type 2 diabetes (T1D, T2D) from other basal insulins to insulin degludec improved glycemic control while significantly reducing hypoglycemia risk at 6 months. For patients with T1D and T2D, A1C decreased by a mean of −0.20% (95% confidence interval [CI]: −0.24%, −0.17%) and −0.51% (95% CI: −0.58%, −0.43%), respectively, vs baseline (all P<0.001).

Dipeptidyl Peptidase-4 Inhibitors Show Better Glycemic Durability Compared to Sulfonylureas

November 2, 2017. Eight randomized controlled trials were included in this meta-analysis that demonstrated the superior durability of glycemic response for dipeptidyl peptidase-4 (DPP-4) inhibitors vs sulfonylureas (SUs) in patients with type 2 diabetes. Changes in A1C levels were compared from an intermediate timepoint of 26 or 52 weeks’ treatment to 104 weeks.

Animas Closes Insulin Pump Business

October 28, 2017. Animas Corporation, a Johnson & Johnson Diabetes Care company, is discontinuing the manufacture and sale of insulin pumps and exiting the insulin pump market. Current users of the Animas Vibe and OneTouch Ping insulin pumps will be transferred to a Medtronic pump. Read more about the announcement here.